The 2025 American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida, begins on December 6. This year, several abstracts across hematologic malignancies are poised to be practice-changing.
To find out which abstracts are most important to Targeted Oncology readers, we’re launching a series of polls to identify the most exciting research results in multiple myeloma, chronic lymphocytic leukemia (CLL), myelofibrosis, acute myeloid leukemia (AML). Voting is now open on LinkedIn and X.
What Are the Top Abstracts to Watch in Multiple Myeloma at the ASH 2025 Meeting?
Poll 1: Which of these myeloma abstracts are you most anticipating at ASH 2025?
Vote Now: X | LinkedIn
LBA-1: Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-inhuman phase 1 study of KLN-1010
LBA-6: Phase 3 randomized study of teclistamab plus daratumumab vs investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with RRMM: Results of MajesTEC-3
92: Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
697: Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in newly diagnosed MM: Initial Results from the window of opportunity phase 1/2 LINKER-MM4 trial
What Are the Top Abstracts to Watch in CLL at the ASH 2025 Meeting?
Poll 2: Which of these CLL abstracts are you most anticipating at ASH 2025?
Vote Now: X | LinkedIn
LBA-3: Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/small lymphocytic leukemia (SLL): First results from a randomized phase III study examining a noncovalent BTK inhibitor in untreated patients
683: Pirtobrutinib vs ibrutinib in treatment-naive and relapsed/refractory CLL/SLL: Results from the first randomized phase 3 study comparing a noncovalent and covalent BTK inhibitor
5669: Zanubrutinib and venetoclax for treatment-naive CLL/SLL, including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA arm D
88: Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients with R/R CLL/SLL who had failed BTK inhibitors
What Are the Top Abstracts to Watch in Myelofibrosis and AML at the ASH 2025 Meeting?
Poll 3: Which of these abstracts in myelofibrosis and AML are you most anticipating at ASH 2025?
Vote Now: X | LinkedIn
768: Preliminary antileukemia activity from a phase 1 study of CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in R/R AML and myelodysplastic syndrome
1645: Tuscany study demonstrates safety and efficacy of tuspetinib plus standard-of-care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy
910: Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK inhibitor-naive myelofibrosis: 96-week results from the phase 3 MANIFEST-2 study
484: Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients with myelofibrosis: Preliminary results from dose escalation of 2 global phase 1 studies
What Are the Top Abstracts to Watch in Other Hematologic Malignancies at the ASH 2025 Meeting?
Poll 4: Which of these abstracts in other hematologic malignancies are you most anticipating at ASH 2025?
Vote Now: X | LinkedIn
LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia who failed first-line corticosteroid treatment
65: Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma: First results from part 1 of the phase 3 Olympia-3 study
817: MaaT013 for ruxolitinib-refractory acute graft-vs-host disease with gastrointestinal involvement: Results from the ARES phase 3 trial
272: Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study
By voting on these polls, you’ll help inform our coverage and ensure we bring you the most important news coming out of the ASH 2025 Meeting and Exposition. The ASH Meeting offers a platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives to meet, share, and learn about the latest in hematologic malignancies, from groundbreaking discoveries to cutting-edge treatments.
